NCT01713309

Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)

Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With Granulocyte Colony-stimulating Factor (Filgrastim)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Helsinki University Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study of plasma HBP -levels of a previously published trial of G-CSF in critically ill patients (Pettila et al. Critical Care Medicine 2000). The original study was a prospective, randomised, double-blind, placebo-controlled trial of filgrastim in patients with acute respiratory failure requiring intubation. In this substudy, the investigators evaluated the effect of filgrastim on HBP -concentrations in critically ill patients.

Conditions

• Acute Respiratory Failure
• Critically Ill

Interventions

Type	Name	Description
DRUG	Filgrastim	Filgrastim 300 ug daily for 7 days, subcutaneously.

Timeline

• Start date: 1996-01-01
• Primary completion: 1998-06-01
• Completion: 1998-09-01
• First posted: 2012-10-24
• Last updated: 2012-10-29

Locations

1 site across 1 country: Finland